MIRM News and Press, Mirum Pharmaceuticals Inc. From 12/09/25

2025-12-09 08:15:11 ET Morgan Stanley analyst issues OVERWEIGHT recommendation for MIRM on December 9, 2025 12:56PM ET. The previous analyst recommendation was Overweight. MIRM was trading at $67.9 at issue of the analyst recommendation. The overall analyst consensus : B...

2025-12-08 17:06:19 ET from Evercore ISI issued a price target of $94.00 for MIRM on 2025-12-08 20:57:28. The adjusted price target was set to $94.00. At the time of the announcement, MIRM was trading at $67.9. The overall price target consensus is at $95.20 with high pr...

2025-12-08 16:17:18 ET Mirum Pharmaceuticals, Inc. (MIRM) M&A Call December 8, 2025 8:30 AM EST Company Participants Meredith Kiernan Christopher Peetz - CEO & Director Joanne M. Quan - Chief Medical Officer Peter Radovich - COO & President ...

2025-12-08 11:23:07 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript Mirum Pharmaceuticals, Inc. (MIRM) Q3 2025 Earnings Call Transcript Mirum aims for $500M–$510M 2025 revenue...

2025-12-08 10:06:22 ET from Cantor Fitzgerald issued a price target of $130.00 for MIRM on 2025-12-08 14:43:28. The adjusted price target was set to $130.00. At the time of the announcement, MIRM was trading at $66.955. The overall price target consensus is at $88.20 wit...

2025-12-08 09:15:03 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for MIRM on December 8, 2025 02:43PM ET. The previous analyst recommendation was Overweight. MIRM was trading at $66.22 at issue of the analyst recommendation. The overall analyst consensus...

-Planned acquisition of brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations -Anticipated to be highly synergistic with Mirum’s liver expertise and proven global commercial capabilities -HDV: Large, high unmet-need rare liver d...

2025-12-03 06:30:00 ET Some stocks perform exceptionally well and garner lots of attention for it. They might even pick up catch nicknames like the "Magnificent Seven" stocks along the way. Other stocks, though, deliver tremendous gains, yet they remain under the radar for most investor...

2025-12-02 16:23:24 ET Mirum Pharmaceuticals, Inc. (MIRM) Evercore 8th Annual Healthcare Conference December 2, 2025 2:10 PM EST... Read the full article on Seeking Alpha For further details see: Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare C...

Proof-of-concept study underway for investigational oral therapy in Fragile X syndrome; top-line data from Phase 2 expected in 2027 Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that the first participant has been enrolled in the BLOOM Pha...